T cells are most important from basic research to therapeutic approaches and play a pivotal role in many diverse application fields such as basic immunology, immuno-oncology, infectious diseases, auto ...

GlaxoSmithKline (GSK) and Miltenyi Biotech said they will partner to develop new cell and gene therapies through a collaboration whose value was not disclosed. The collaboration is designed to combine ...

BOSTON, Massachusetts and BERGISCH GLADBACH, Germany, May 4, 2010 /PRNewswire/ -- Stemgent, Inc., and Miltenyi Biotec today announced a strategic collaboration for co-development and commercialization ...

NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...

Miltenyi Biotec, the German cell and gene therapy (CGT) specialist that quietly powers much of the world’s CAR‑T ...

SANTA BARBARA, Calif. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that it has completed acquisition of Owl biomedical, Inc., an emerging company developing and ...

GSK and Miltenyi Biotec has announced a strategic collaboration that will bring together GSK’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s global leadership ...

This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field and how we as experts at Miltenyi Biotec can assist your IO research. We want to ...

First product for fedbatch CHO processes has been launched following testing with 11 cell lines and clones. Germany-based biotech products and services firm Miltenyi Biotec has teamed up with cell ...

Germany's Miltenyi Biotec is exploring local manufacturing of cell and gene therapies in India, aiming to expand clinical access and potentially develop the country as a regional CGT hub ...

Biomedical and clinical research company Miltenyi Biotec says that it has fully restored systems after a malware attack that took place last month and affected the firm's global IT infrastructure.

CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...